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Numerous cellular functions rely on an active proteasome allowing degradation of damaged or misfolded
proteins. Therefore changes in the proteasomal activity have important physiological consequences.
During oxidative stress the production of free radicals can result in the formation of 4-hydroxynonenal
(HNE) following lipid peroxidiation. The HNE moiety is highly reactive and via a nucleophilic attack
readily forms covalent links to cysteine, histidine and lysine side chains. However, as the chemical
properties of these amino acids differ, so does the kinetics of the reactions. While covalent linkage
through Michael addition is well established, reversible and unstable associations have only been in-
dicated in a few cases. In the present study we have identiﬁed an unstable HNE adduct on the α7 subunit
of the 20S proteasome using phage display of recombinant antibodies. This recombinant antibody
fragment recognized HNE modiﬁed proteasomes in vitro and showed that this epitope was easily HNE
modiﬁed, yet unstable, and inﬂuenced by experimental procedures. Hence unstable HNE-adducts could
be overlooked as a regulatory mechanism of proteasomal activity and a participating factor in the de-
creased proteasomal activity associated with oxidative stress.
& 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The proteasome is a barrel-shaped intracellular multicatalytic
protease responsible for a highly controlled degradation of target
proteins [1]. In humans, the core proteasome (20S) is composed of
four heptameric rings consisting of α and β subunits in the order
α1-7, β1-7, β1-7, α1-7 to form a hollow cylinder [2, 3]. The α
subunits are believed to form a gated entry to guide proteins
destined for degradation into the proteolytic center formed by the
β-subunits [4]. Only three subunits, β1, β2 and β5, projecting their
N-terminal end into the inner chamber, contain catalytically active
threonine residues (Thr1) and show nucleophile hydrolase activ-
ity: peptidylglutamyl-peptide-hydrolysing-activity, trypsin-likeInc. This is an open access article u
re proteasome; MHC, major
me; TFA, Triﬂuoroacetic acid;
; MPBS, milk PBS; scFv, single
araformaldehyde; FF95, neo-activity and chymotrypsin-like activity, respectively. The protea-
some is absolutely essential for cell homeostasis and survival as it
degrades damaged or misfolded proteins. Furthermore, the pro-
teasome is in part responsible for the tight regulation of protein
turnover of key proteins in the cell cycle, as well as, transcription
factors. Within the immune system, the proteasome is responsible
for the partial degradation of invading antigens, ultimately al-
lowing the presentation of short peptides on the major histo-
compatibility complex (MHC) molecules [1,5–7].
For a number of diseases, a decline in proteasome activity has
been reported, potentially explaining the build-up of damaged or
misfolded proteins in aggregates associated with certain diseases
such as atherosclerosis, Parkinson’s disease and Alzheimer’s dis-
ease [8–12]. Proteasomal activity has also been reported to change
during normal development and aging [13–15]. However, the de-
cline in proteasomal activity may not always follow a decrease in
the cellular content of the proteasome [15,16], pointing to other
modulatory mechanisms of the proteolytic activity. Here, the cor-
relation between an increased level of the oxidant 4-hydro-
xynonenal (HNE) and the decline in proteasome activity are ofnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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stress, formed by lipid peroxidation of polyunsaturated fatty acids
in e.g. cholesterol, phospholipids and triglycerides. HNE is highly
reactive and able to readily modify the sulfhydryl group of cysteine
residues and imidazole group of histidine residues, while the ε-
amino group of lysine residues serves as a less active target for
nucleophilic attack by HNE [18,19]. Furthermore, HNE is able to
introduce protein crosslinks, thus giving rise to protein aggregates
[20,21]. The deleterious effects of HNE protein modiﬁcation on a
molecular level, has been studied for a number of intracellular
proteins, where HNE modiﬁcation lead to an alteration of protein
structure and/or inhibition of protein function [22–24]. Thus, re-
cent evidence suggests HNE as an important contributing factor in
introducing the pathological effects associated with oxidative
stress.
Proteins modiﬁed by HNE show increased proteolytic suscept-
ibility for removal by the proteasome. On the other hand, excessive
HNE modiﬁcation of investigated target protein was shown to
inhibit proteasomal degradation, leading to an accumulation of
non-degradable compounds and even proteasome inhibition
[17,21,25,26]. Interestingly, it has also been demonstrated that the
proteasome itself is susceptible to site-speciﬁc HNE modiﬁcation
both in vitro and in vivo. An increase in HNE modiﬁed proteasome
correlated with a decrease in proteasome activity in Alzheimer’s
disease patients[9,27]. Furthermore, site and tissue-speciﬁc HNE
modiﬁcation patterns of proteasome inhibition have been ob-
served in rat liver proteasome, cardiac muscle after reperfusion,
cerebral ischemia and lymphocytes from aged individuals
[14,15,28–30].
Because of the essential importance of the proteasome, it
would be of great interest to further elucidate the molecular basis
of the observed HNE induced proteasome inhibition. Previously,
mass spectrometry analysis or antibodies recognizing general
HNE-adducts have been applied to detect and quantify HNE
modiﬁcations. However, only HNE Michael adducts to cysteine and
histidine residues constitute essential irreversible modiﬁcations
[18,31,32], whereas Michael adducts to lysine are readily re-
versible and therefore might escape detection. Furthermore, HNE
is able to form a lysine ε-amino Schiff base that is readily re-
versible [31,33]. These unstable HNE adducts are very likely to be
important in the sensing of oxidative stress; however, harsh ex-
perimental settings may eliminate these labile HNE-adducts,
leaving only a sub-set to be investigated [33]. General HNE speciﬁc
antibodies are commercially available but most cannot fully dis-
criminate between cystein, histidine or lysine HNE adducts.
The purpose of this study was to select and characterize spe-
ciﬁc antibodies against HNE-modiﬁed proteasome utilizing the
antibody phage display technique. More speciﬁcally we aimed to
obtain antibodies recognizing combined epitopes, able to target
speciﬁc HNE modiﬁcations on the proteasome. The α7 subunit of
the proteasome was chosen as target in this study, as it has pre-
viously been shown to be an important regulator of assembly and
stability of functional proteasomes [34]. Binding of HNE to the α7
subunit of the proteasome could hence constitute a regulatory
mechanism of proteasomal activity.
Recombinant human proteasome subunit α7 modiﬁed in vitro
by HNE was used for selection. The speciﬁcity of the antibodies
obtained was veriﬁed in ELISA and Western immunoblotting,
whereas the dynamic of the recognized epitope was characterized
in cell culture and on puriﬁed 20S proteasomes. We report that the
quantity of an HNE adduct on proteasome subunit α7 increased in
FF95 cells when exposed to increasing amounts of HNE. This HNE
adduct was found to be easily HNE modiﬁed, yet unstable, sug-
gesting that labile HNE-adducts could be an overlooked and par-
ticipating factor in HNE induced proteasome dysfunction.2. Material and methods
2.1. Expression of proteasome subunit α7
Proteasomal subunit DNA for α7 (imaGenes – full length hu-
man cDNA: IRAUp969A0718D) was subcloned into pET22B (Merck
KGaA, Germany) and transformed into BL21 GOLD by electro-
poration (Agilent Technologies). Protein expression was induced
by addition of 1 mM IPTG at OD600¼0.6 and cultures were left to
express 16 hours (h), 20 °C at 200 RPM in a shaking incubator
(New Braunswick). Cells were harvested and cytoplasmic proteins
were released by sonication (LABSONIC M). Cell debris was pel-
leted (20000 g, 40 min, 4 °C), and cleared cell lysate was loaded
onto a 5 ml HisTrap HP column (GE healthcare) to capture 6xpo-
lyhistidine tagged proteasome subunit α7 using a ÄKTA Explorer
FPLC (Amersham). The column was washed with 5 column vo-
lumes (CV) of binding buffer (50 mM NaH2PO4, 300 mM NaCl,
40 mM imidazole, pH 8) and 5 CV of high salt washing buffer
(50 mM NaH2PO4, 1000 mM NaCl, 40 mM imidazole, pH 8). Target
protein was eluted applying a constant gradient ranging from
40 mM to 400 mM imidazole in 30 fractions of 1.5 ml. Protein
content and purity was veriﬁed by SDS-PAGE and Western im-
munoblotting. Fractions containing protein were pooled and dia-
lyzed against TKK buffer (25 mM KH2PO4, 100 mM KCL, pH 7.4) to
remove imidazole. Protein concentration was measured at 260 nm
on a Nanodrop 1000 spectrophotometer (Thermo Fisher
Scientiﬁc).
2.2. In vitro HNE modiﬁcation of proteasome subunit α7
HNE was activated by adding 20 μl HNE(OCH3)2 (Sigma, 396
nmol) to 200 μl of acetonitrile with 0.05% Triﬂuoroacetic acid
(TFA) and mixed thoroughly. Next 200 μl of dH20, 0.05% TFA was
added and mixed. Finally 400 μl dH2O was added and mixed be-
fore measuring HNE absorbance at 224 nmwith a molar extinction
coefﬁcient of 13750 M/cm. For HNE modiﬁcation of proteasome
subunit α7 a target concentration of 100 μM activated HNE and
175 μg/ml proteasome subunit in TKK buffer was made. The re-
action was set up at 37 °C for 30 min and stopped by removing free
HNE by dialysis. As a control for downstream testing, a similar
amount of proteasome subunit was submitted to the same pro-
cedure, omitting HNE(OCH3)2.
2.3. Single round selection and screening with phage antibodies on
proteasome subunit α7
HNE modiﬁed proteasome subunit α7, 50 μg/ml in TKK buffer,
was immobilized in a 4 ml MaxiSorp immunotube (Thermo Fisher
Scientiﬁc) overnight at 4 °C. The immunotube was then rinsed in
phosphate buffered saline (PBS, Sigma Aldrich) and blocked in PBS
with 4% w/v Marvel brand skimmed milk powder (4% MPBS,
Premier Foods) for 2 h at room temperature (RT). A naïve single
chain variable fragment (scFv) phage library, the YAMO library[35],
was then added at a concentration of 1012 phages/ml in 4% MPBS.
Incubation was carried out for 2 h on a roller table at RT. The
immunotube was washed with 75 ml of PBS, 0.05% Tween 20
(PBS-T, Merck) and then with 75 ml PBS. Bound phages were
eluted with trypsin-PBS (1 mg/ml, Sigma) and used to infect ex-
ponentially growing TG1 E. coli. Infected cells were plated on TYE
plates (1% w/v glucose, 100 mg/ml ampicillin) and left at 30 °C
overnight. Individual clones were picked into 96-well culture
plates with 100 ml 2xTY containing 1% glucose and 100 mg/ml
ampicillin. Cultures were grown overnight at 37 °C in a shaking
incubator.
Phage antibodies were produced by superinfection with the
KM13 helper phage [36] and individual phage antibody clones
Fig. 1. Expression and puriﬁcation of proteasomal subunit α7. (A) Comassie stained
gel of IMAC puriﬁed α7 separated by SDS-PAGE. One clear band was observed at
30 kDa corresponding to the theoretical size of α7 plus the added tag-sequence.
(B) Western immunoblot using a commercial anti-α7 antibody to probe for: 1: 20S
proteasome, 2: HNE-20S, 3: α7, 4: HNE-α7. For detection of primary antibody a
secondary swine-anti-rabbit-HRP was applied. Protein loads were 0.5 μg for each
lane.
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binding HNE modiﬁed proteasome subunit α7 were screened in
monoclonal antibody-phage ELISA in 96-well MaxiSorp plates
(Thermo Fisher Scientiﬁc) coated with either HNE modiﬁed α7
(10 μg/ml), unmodiﬁed α7 (10 μg/ml) or 4% MPBS. Monoclonal
phage ELISA was performed as described previously [37].
2.4. Expression and puriﬁcation of soluble antibodies in Leishmania
tarentolae T7-TR
Sub-cloning, expression and puriﬁcation of selected scFv fused
to the Fc-region of rabbit IgG (anti HNE-α7) was conducted as
previously described [38]. Secreted proteins in the supernatant
were ammonium sulphate precipitated, resuspended in protein A
Binding buffer and anti HNE-α7 puriﬁed on a Protein A HP spin-
Trap (GE Healthcare) according to protocol. Antibody purity and
successful incorporation of the rabbit Fc region were analysed by
means of SDS-PAGE and Western immunoblotting. Puriﬁed anti-
body concentration was measured at 280 nm on a Nanodrop 1000.
2.5. Anti HNE-α7 speciﬁcity ELISA
Speciﬁcity of the anti HNE-α7 antibody was screened by ti-
tration ELISA in 96-well ﬂat bottomed Maxi-Sorp plates coated
with different antigens: HNE-α7, α7, HNE-α3, HNE-β6, HNE-D11,
HNE BSA, MPBS (HNE-antigens were modiﬁed as described above).
All antigens were coated at a concentration of 5 μg/ml overnight at
4 °C. The wells were washed 3  5 min in PBS and then blocked in
2% MPBS for 1 h at RT. Blocking solution was discarded and anti
HNE-α7 at different concentrations was added to each well and
left to incubate for 1 h at RT under gentle agitation. The wells were
washed 3  5 min in PBS-T before addition of swine-anti-rabbit-
HRP (diluted 1:3000, Dako-cat nr. P0217) secondary antibody for
1 h at RT. TMB readymade substrate (Life Technologies) was added
and the chromogenic reaction was quenched by 1 M sulphuric acid
(H2SO4) before reading the absorbance at 455 nm in a plate reader
(Bio-Rad, model 550).
2.6. Cell handling
Foreskin ﬁbroblasts (FF95 cells) [39] were used between pas-
sage 8–18, and maintained in DMEM (Biochrom) supplemented
with 10% fetal calf serum (FCS, Biochrom), and grown at 37 °C, 5%
CO2 and 95% RH. When passaged, cells were detached with tryp-
sin/EDTA (Biochrom) for 5 min at 37 °C, before resuspending the
cells in complete medium.
2.7. In cell ELISA
For in-cell ELISA, 10.000 FF95 cells were seeded out pr. well in a
96-well tissue culture plate (TPP) and left in the incubator over-
night for attachment. The cells were then rinsed with dPBS (Bio-
chrom) and treated with different concentrations of HNE-dPBS for
30 min at 37 °C. HNE (Cayman Chemical) was activated according
to manufacturer’s instruction. After 30 min incubation, the cells
were rinsed three times with dPBS before either adding complete
medium and re-incubated or being ﬁxed for 15 min at RT in 3%
paraformaldehyde-PBS (3% PFA-PBS). The cells were permeabilized
with 0.25% Triton x-100-PBS for 10 min at RT, washed with PBS
and then blocked in 5% FCS-PBS for 1 h at RT. Incubation with
primary antibody, anti HNE-α7 (10 μg/ml), anti HNE (2 μg /ml,
OXIS International-cat nr. 24325/24327) or anti α7 (1.5 μg/ml,
ProteinTech-cat nr. 11887-1-AP), was carried out for 1 h at RT be-
fore washing 3  5 min in PBS-T. Secondary HRP conjugated an-
tibodies with appropriate host speciﬁcities were applied and in-
cubated for 1 h at RT, washed and developed using ortho-phenylenediamine (OPDA) (Sigma). The chromogenic reaction was
halted by 2.5 M H2SO4 before reading the absorbance at 492 nm in
a plate reader (BioTek, Synergy 2).
2.8. HNE-20S proteasome ELISA
Flat bottomed Maxi-Sorp plates were coated with 20 μg/ml
puriﬁed 20 S proteasome ON at 4 °C. Coated wells were then
rinsed with PBS and treated with 60 μM HNE-PBS (activated as
above) for 30 min at 37 °C. The wells were then rinsed with PBS
and incubated in PBS at 37 °C for 0 or 6 h before being blocked in
5% FCS for 1 h at RT. Primary antibody, anti HNE-α7 (1 μg), anti
HNE (0.2 μg /ml) or anti α7 (0.1 μg/ml), was applied and incubated
for 1 h at RT and completed as described above.
2.9. Statistical analysis
Data are expressed as mean þ/ SEM. The data were statis-
tically compared using a parametric, unpaired Students t-test. The
statistical analysises were performed by statistical software
(GraphPad Prism 6.0, GraphPad Software, Inc.). Deﬁnition of sta-
tistical signiﬁcance: Po0.05.3. Results
3.1. Selection of single chain variable fragment antibodies against
HNE modiﬁed α7
To obtain pure proteasome subunit α7, full-length human α7
cDNA was subcloned into the pET22B vector for periplasmic ex-
pression in E. coli followed by puriﬁcation using immobilized ion
afﬁnity chromatography (Ni-NTA puriﬁcation). The purity was
evaluated by SDS-PAGE while Western immunoblotting using a
commercial antibody against the α7 subunit veriﬁed the identity
(Fig. 1). The α7 subunit appeared as one band at E30 kDa,
matching the theoretical size 28.3 kDa and α7 recognized in pur-
iﬁed 20S proteasomes from human erythrocytes [40], taking into
account the C-terminal tag sequence (polyhistidine-tag, Myc-tag).
Single chain variable fragment (scFv) phage antibodies re-
cognizing the HNE modiﬁed α7 subunit were selected using a
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and the KM13 helper phage[36]. Eluted phages were produced as
phage-antibodies in small-scale and tested by monoclonal phage
ELISA to evaluate binding properties. Individual phage-antibodies
were tested for binding against HNE-α7, α7 and milk PBS. As ex-
pected, most phage-antibodies bound epitopes not affected by the
HNE modiﬁcation. However, twelve phage-antibodies had a HNE-
α7:α7 signal ratio higher than 10, which were selected for further
screening (data not shown) and produced in large scale. To in-
vestigate speciﬁcity, phage-antibodies were applied in titration
ELISA against different antigens. Only two phage-antibodies
proved speciﬁc for HNE-α7 (data not shown). Sequencing revealed
that these antibodies were identical.
3.2. Anti HNE-α7 antibody production in Leishmania Taratolae (TR-
T7)
The Scfv gene was sub-cloned into pMJ-LEXSY-rFc [38], con-
taining the rabbit IgG Fc-encoding region (hinge region and CH2-
CH3 domains). The construct was transformed into TR/T7 and the
anti HNE-α7 antibody was expressed and puriﬁed using protein A
afﬁnity puriﬁcation. The purity was conﬁrmed by SDS-PAGE while
the presence of the Fc-region was veriﬁed by Western im-
munoblotting (Fig. 2). Two clear bands were observed at E53 kDa.
The upper band constitutes full-length anti HNE-α7 antibody,
while the lower band is a truncated version where the myc-tag has
been cleaved off, as observed using mass-spectrometry [38]. A
commercial antibody against rabbit IgG successfully recognized
the anti HNE-α7 antibody.
3.3. Conﬁrmation of anti HNE-α7 antibody speciﬁcity
A titration ELISA against different antigens conﬁrmed the spe-
ciﬁcity of the anti HNE-α7 antibody with no cross-reactivity ob-
served against non-modiﬁed α7, other HNE-proteasome subunits,
HNE-modiﬁed bovine serum albumin, HNE-D11 (a molecular
scaffold based on fatty acid binding protein) or milk PBS (Fig. 3A).
The anti HNE-α7 antibody was then tested for use in Western
immunoblotting. After short-term exposure, target protein (HNE-
α7), was not recognized by the anti HNE-α7 antibody. By contrast,
a commercial antibody against α7 readily detected both α7 and
HNE-α7 (Fig. 1). However, increasing the exposure time dramati-
cally resulted in a faint band recognized by the anti HNE-α7Fig. 2. Expression of anti HNE-α7 antibody in the TR-T7 system. (A) Protein A
puriﬁed anti HNE-α7 antibody were separated by SDS-PAGE and stained with
coomassie. 1: anti HNE-α7 elution 1, 2: anti HNE-α7 elution 2 (B) Western im-
munoblot probed with a commercial antibody against rabbit IgG Fc to verify the
successful incorporation of rabbit Fc. 1: anti HNE-α7 elution 1, 2: anti HNE-α7
elution 2.antibody (Fig. 3B). Hence, only negligible amounts of HNE seemed
to be attached to the recognized epitope on α7 after SDS-PAGE,
indicating a labile HNE-adduct. In an attempt to stabilize the
epitope, HNE-α7 was reduced with sodium borohydride before gel
electrophoresis. Conversely, an adverse effect was observed with
no signal at all (supplementary data, ﬁg. S1). Consequently, the
non-reduced form of HNE (including the aldehyde group) is an
important part of the epitope recognized by the anti HNE-α7
antibody.
3.4. HNE-α7 metabolism in FF95 cells
To verify that the HNE-α7 epitope constitutes a physiological
relevant epitope in living cells, a dose-response experiment was
performed. To reduce the amount of endogenous HNE, human
neonatal foreskin ﬁbroblast (FF95) were chosen, as these are ex-
pected to contain minimal endogenous HNE. The FF95 cells were
treated with varying concentrations of HNE for 30 min at 37 °C.
Using In-Cell ELISA, HNE-α7 and general HNE-adducts were
quantiﬁed (Fig. 4) and a dose-response relationship was observed
for both antibodies. When considering the ratio between the ob-
served signals without HNE treatment compared to the different
concentrations of HNE added, the increase in HNE-α7 was sig-
niﬁcantly larger than the increase in general HNE adducts. Both
antibodies were also applied in immunocytochemistry on HNE-
treated FF95 cells and images were obtained by confocal laser
scanning microscopy. Quantitative immunoﬂuorescence revealed
an identical pattern as observed in the In-Cell ELISA (results not
shown). In addition, a 20S proteasome activity assay on FF95 cell
lysate showed that increasing amounts of HNE (430 μM) did in
fact decrease proteasome activity (supplementary data, ﬁg. S2).
To investigate the metabolism of HNE-α7, FF95 cells were
treated with 30 and 60 μM HNE for 30 min at 37 °C and then left
to recover in complete medium for the speciﬁed time points
(Fig. 5). A half-life of approximately 6 h was observed for HNE-α7
at both treatment conditions compared to a half-life of approxi-
mately 10 and 18 hours for general HNE adducts at 60 μM and
30 μM HNE treatment respectively. Moreover, re-addition of HNE
after a six-hour recovery period surprisingly revealed only a small
increase in HNE-α7 (10–20%) whereas general HNE-adducts in-
creased considerably more (40–66%) compared to initial amount
observed at zero hours. To ensure that proteasome levels were the
same in these conditions, a commercial antibody against α7 was
applied to quantify α7. No difference in α7 levels was observed
between different treatment conditions.
Previous studies have shown that removal of HNE modiﬁed
proteins is usually carried out by either degradation by the pro-
teasomal system or by lysosomal autophagy [17, 41]. To examine if
these systems were responsible for HNE-α7 turnover, the protea-
some inhibitor lactacystin and the lysosomal inhibitor Con-
canamycin A were included in a recovery experiment similar to
above. Inhibition of either system had only minimal effect on the
turnover of HNE-α7 (Supplementary data, ﬁg. S3).
3.5. HNE-α7 turnover on puriﬁed 20 S proteasome
As the Western immunoblotting performed on HNE modiﬁed
α7 indicated that the epitope involving the HNE modiﬁcation on
α7 might be labile (Fig. 1B), we wanted to examine whether a si-
milar trend could be observed on puriﬁed 20 S proteasome. Pur-
iﬁed 20S proteasome was treated with 60 μM HNE for 30 min,
before recovery in PBS-only for 6 h at 37 °C. For HNE-α7 an almost
identical turnover as in FF95 cells were observed whereas general
HNE-adducts only decreased minimally during recovery (Fig. 6),
strongly indicating a labile HNE-adduct recognized by the anti
HNE-α7 antibody.
Fig. 3. The selected anti HNE-α7 antibody shows a high speciﬁcity. (A) Titration ELISA against different antigens at different concentrations. Antigens (5 μg/ml) used: HNE-α7,
α7, HNE-α3, α3, HNE-β6, HNE-D11, HNE-BSA (bovine serum albumin) and MPBS (milk PBS). Primary antibody: rabbit anti HNE-α7. Secondary antibody: Swine-anti-Rabbit
HRP (DAKO). Values are expressed as the means þ/- SEM for 3 replicates per group. (B) Western immunoblot of (0.5 μg): 1: HNE-α7, probed with the anti HNE-α7 antibody
and secondary antibody (swine-anti-rabbit-HRP). An exposure time of 8 h was used.
Fig. 4. In-cell ELISA quantiﬁcation of protein-HNE adducts in FF95 cells treated with HNE. (AþB) FF95 cells were treated with different amounts of HNE for 0.5 h and ﬁxed.
HNE modiﬁed proteins were detected with a mouse monoclonal anti-HNE antibody (A) while HNE-α7 was quantiﬁed using the anti HNE-α7 antibody (B). Values are
expressed as the means þ/- SEM for n¼5 per group. * For A and B “Janus whole cell stain” was used to correct for well-to-well variation of cell numbers. * statistical
signiﬁcance: Po0.05.
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HNE modiﬁcation of proteins has long been recognized as an
important post-translational modiﬁcation, given that the HNE
moiety is extremely reactive and via a nucleophilic attack forms
covalent links to cysteine, histidine and lysine side chains. How-
ever as the chemical properties of these amino acids differ, so does
the kinetics of the reactions. Reaction with the ε -amino group of
lysine has been shown to be readily reversible, thus this interac-
tion may be overlooked in normal biochemical assays, as the
equilibrium may favour dissociation. It can, however, be hy-
pothesized that such reversible binding of HNE to the α7 subunit
of the proteasome could constitute a regulatory mechanism of
proteasomal activity. This could potentially explain a decreased
proteasomal activity associated with elevated levels of HNE fol-
lowing oxidative stress. When treating different cell lines with low
to medium concentrations of HNE a hormetic effect is often ob-
served, point to HNE being a putative second messenger in oxi-
dative stress. In this regard an unstable HNE modiﬁcation, as
identiﬁed in this study, could prove to be instrumental [42].
While it would be problematic to raise conventional hybridoma
antibodies recognizing epitopes with contribution both from the
HNE moiety and the α7 subunit amino acid sequence, due to po-
tential lack of immunogenicity of such unstable epitopes, the
generation of recombinant antibodies via in vitro selection ofphage display libraries could be feasible. This is especially true as
the capture of antibodies in vitro only rely on binding, contra
in vivo immunogenicity. Furthermore, the application of one se-
lection round only, made possible by the application of the KM13
helper phage [36], resulted in a large diversity of binders, most of
which recognized epitopes present on the unmodiﬁed α7 subunit.
Previously, phage display selection of recombinant antibody li-
braries were used to generate binders toward post-translational
modiﬁcations independent of sequence context [43].
In this study we generated a recombinant antibody binding to a
shared epitope between HNE and the amino acid sequence of α7.
This HNE-adduct epitope was shown to increase in FF95 cells and
on puriﬁed 20S proteasomes when exposed to HNE. The HNE-
adduct had a rapid turnover. It was not affected by inhibition of
either the proteasomal system or lysosomal autophagy and was
found to constitute a spontaneusly unstable linkage of HNE to the
proteasomal subunit. In support of this, the puriﬁed 20S protea-
somes used in the HNE-20S assay (Fig. 6) were adsorbed to the
ELISA wells. Hence, no 20S proteasome, other cell machinery or
metal ions were present during the assay that could potentially
inﬂuence the HNE-α7 adduct. However, other autophagic path-
ways exist and could affect the turnover of this adduct in vivo. The
commercial antibody against general HNE-adducts used in this
study had a higher afﬁnity for HNE-histidine adducts compared to
HNE-lysine or HNE-cysteine adducts (as indicated by the
Fig. 5. Recovery In-cell ELISA. FF95 cells were treated with different amounts of HNE for 0.5 h, and then incubated with complete medium for recovery at speciﬁed time
points. (A) HNE modiﬁed proteins were detected with a mouse monoclonal anti-HNE antibody. (B) HNE-α7 was quantiﬁed using the anti HNE-α7 antibody. (CþD) Quan-
tiﬁcation of cellular α7 and corrected values of HNE-α7. Values are expressed as the means þ/- SEM for n¼5 per group. * For A and B “Janus whole cell stain” (thermo) was
used to normalize the data, to account for well to well variation of cell numbers. ** for C and D a commercial antibody against α7 was used to correct for variation of the
amount of α7. * statistical signiﬁcance: Po0.05.
J. Just et al. / Free Radical Biology and Medicine 89 (2015) 786–792 791manufacturer). HNE-histidine Michael adducts are often stable
and since PBS offers no pathways to metabolize these, it seemed
reasonable that almost no turnover was observed in PBS only.
Thus, it appears that although HNE readily forms adducts to the
20S proteasome, part of these adducts might be unstable and
therefore not detected in standard experimental settings. It would
be of interest to determine the physiological effect of these un-
stable HNE-adducts. In an attempt to determine the impact of the
HNE-adduct recognized by anti HNE-α7 on proteasome activity, aFig. 6. ELISA quantiﬁcation of protein HNE adducts in puriﬁed 20S proteasome treated w
anti-HNE antibody. B: HNE-α7 was quantiﬁed using the anti HNE-α7 antibody. C: prote
Values are expressed as the means þ- SEM for n¼3 per group. Data was corrected for
signiﬁcance: Po0.05.recovery experiment with puriﬁed 20S proteasomes treated with
HNE was carried out with or without the anti HNE-α7 antibody. It
was observed that proteasome activity was lower (approx. 10%)
after a 6 hour recovery period when including the anti HNE-α7
antibody in the recovery medium. One possible explanation being
that anti HNE-α7 stabilizes the HNE-adduct, which in turn locks
the proteasome in a decreased activity state. Further investigation
is needed to clarify this. However it could prove difﬁcult to address
the speciﬁc impact of the HNE-α7 adduct described in this study.ith 60 μM HNE A: HNE modiﬁed proteins were detected with a mouse monoclonal
asomal 20S subunit α7 was quatiﬁed with a commercial rabbit polyclonal against.
each condition and antibody to a well treated with 60 μM HNE only. * statistical
J. Just et al. / Free Radical Biology and Medicine 89 (2015) 786–792792When cells or puriﬁed proteasomes are treated with HNE a ple-
thora of HNE-adducts is created, stable and unstable, and poten-
tially masking the effect of individual effect of speciﬁc HNE-
adducts.
In conclusion, unstable HNE-adducts might not, as in this case,
be as easily detected as stable HNE-adducts, but could nevertheless
serve as a marker of acute oxidative stress. Furthermore, the effect
of these unstable modiﬁcations remain largely uninvestigated and
might be a participating factor in introducing the deleterious effects
observed at the proteasome level by HNEAcknowledgements
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